Etanercept on steroid-refractary acute graft-versus-host disease
Autor: | Silvia González Munguía, Moisés Pérez León, Marta Piñero González, Marina Magnolia Díaz Pestano, Rafael Molero Gómez, Hugo Daniel Luzardo Henríquez |
---|---|
Jazyk: | English<br />Spanish; Castilian |
Rok vydání: | 2015 |
Předmět: | |
Zdroj: | Farmacia Hospitalaria, Vol 39, Iss 3, Pp 147-151 (2015) |
Druh dokumentu: | article |
ISSN: | 1130-6343 2171-8695 |
DOI: | 10.7399/fh.2015.39.3.8000 |
Popis: | Objetive: To describe etanercept use and effectiveness on steroid- refractary acute graft-versus-host disease after hematopoietic cell transplantation. Method: Patients treated with etanercept as off label use for steroid-refractary acute graft-versus-host disease were selected and each patient’s medical history was reviewed to assess the clinical response. Results: The study included five patients: four presented with digestive manifestations and one presented pulmonary and liver manifestations. 80% of patients showed a clinical response: 60% a partial response and 20% a total response. In four cases etanercept 25mg was administered twice a week with variable duration of treatment, achieving no response in 1 case (3 weeks), partial response in two 2 cases (4 weeks and 8 weeks) and a complete response in 1 case (8 week period). Only one case was treated with etanercept 50mg administered twice a week for 5 weeks with a partial treatment response. Conclusions: The clinical response rate is consistent with the previously published data. This updates the scarce bibliographic information about etanecept use in steroid-refractary acute graft-versus-host disease. Due to clinical design limitations and the small patient population, future clinical studies should be conducted to assess the efficacy and security of etanercept in these patients. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |